Co-Diagnostics, Inc. — Investor Relations & Filings

Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and markets advanced diagnostic technologies. The company's core platform is centered on its patented Co-Primers technology, a unique molecular configuration that enhances Polymerase Chain Reaction (PCR) performance by significantly reducing the formation of primer dimers, a primary cause of inaccurate results. This innovation enables the creation of more sensitive and specific diagnostic tests, minimizing false positives and false negatives. Co-Diagnostics provides a range of solutions targeting infectious diseases. Its product portfolio includes reagents for laboratory use, research-use-only (RUO) applications, and vector control. The company is also developing the Co-Dx PCR platform, an integrated system designed to bring rapid, real-time PCR testing to point-of-care and at-home settings, aiming to democratize access to molecular diagnostics.